Eloxx Pharmaceuticals Inc (ELOX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$
Buy
$
$ (+%)
Eloxx Pharmaceuticals Inc is a United States-based clinical-stage pharmaceutical company. It is focused on building and developing a portfolio of therapeutics for the treatment of cancer and immunological diseases.
Prices updated at 14 May 2025, 07:58
| Prices minimum 15 mins delay
|
Prices in USD
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Tomer Kariv
CEO
Mr. Sumit Aggarwal
Most recent earnings
31 Dec 2022
Fiscal year end
31 Dec 2022
Employees
18
Head office
480 Arsenal Way
Watertown
United States
02472
Key personnel
| Owner name | Salary | Bonus | All other compensation | Total compensation | Restricted stock award |
|---|---|---|---|---|---|
Mr. Steven D. Rubin Independent Director | 0.06m | - | - | 0.06m | - |
Mr. Tomer Kariv Chairman of the Board | 0.05m | - | - | 0.05m | - |
Mr. Daniel E. Geffken, M.B.A. Interim Chief Financial Officer and Principal Accounting Officer | - | - | - | 0.06m | - |
Mr. Sumit Aggarwal Director, President and Chief Executive Officer | 0.58m | - | - | 1.40m | - |
Dr. Alan Walts Independent Director | 0.06m | - | - | 0.06m | - |
Ms. Lindsay Androski Independent Director | 0.03m | - | - | 0.03m | - |
Top 5 shareholders
| Owner name | No. of shares | Share as % of port. | Last change | Portfolio % change | Date of portfolio | % Total assets |
|---|---|---|---|---|---|---|
| Northern Trust Investments Inc | 101 | - | - | - | 30 Apr 2025 | 0.00 |
| NT Quality SCC US Fund - L | 101 | - | - | - | 30 Apr 2025 | 0.00 |
| Northern Trust Asset Management | - | - | -101 | - | 30 Apr 2025 | - |
| Meeder Asset Management Inc | - | - | -15 | - | 30 Apr 2025 | - |
| Northern Trust Investments N A | - | - | -7305 | -100 | 30 Apr 2025 | - |
Director dealings
| Date | Action | Name | Price | Value | No. of shares | Holding (%) | Additional info |
|---|---|---|---|---|---|---|---|
| 16 Oct 2024 | - | Mr. Steven D. Rubin | - | - | 12,000 | - | - |
| 16 Oct 2024 | - | Mr. Sumit Aggarwal | - | - | 169,930 | - | - |
| 16 Oct 2024 | - | Dr. Alan Walts | - | - | 12,942 | - | - |
| 16 Oct 2024 | - | Ms. Lindsay Androski | - | - | 12,000 | - | - |
| 24 Jan 2024 | - | Mr. Steven D. Rubin | - | - | 7,500 | - | - |
| 24 Jan 2024 | - | Mr. Sumit Aggarwal | - | - | 60,000 | - | - |
| 24 Jan 2024 | - | Dr. Alan Walts | - | - | 7,500 | - | - |
| 24 Jan 2024 | - | Ms. Lindsay Androski | - | - | 7,500 | - | - |
| 24 Jan 2025 | - | Mr. Steven D. Rubin | - | - | 15,750 | - | - |
| 24 Jan 2025 | - | Mr. Steven D. Rubin | - | - | 3,750 | - | - |
| 24 Jan 2025 | - | Mr. Sumit Aggarwal | - | - | 199,930 | - | - |
| 24 Jan 2025 | - | Mr. Sumit Aggarwal | - | - | 30,000 | - | - |
| 24 Jan 2025 | - | Dr. Alan Walts | - | - | 3,750 | - | - |
| 24 Jan 2025 | - | Dr. Alan Walts | - | - | 16,692 | - | - |
| 24 Jan 2025 | - | Ms. Lindsay Androski | - | - | 15,750 | - | - |
| 24 Jan 2025 | - | Ms. Lindsay Androski | - | - | 3,750 | - | - |
Please note that past performance is not a reliable indicator of future returns.
